Exosome-based Protein/Small Molecule Delivery
Undisclosed
PreclinicalActive
Key Facts
About ReNeuron
ReNeuron is a public biotechnology company transitioning from a pioneer in clinical-stage regenerative medicine to a focused exosome platform developer. Its core asset is the CustomEX™ platform, which utilizes a library of proprietary, conditionally immortalized stem cell lines to produce exosomes with innate tissue-targeting capabilities for drug delivery. The strategy is to advance internal pipeline candidates and establish strategic partnerships, building on a legacy that includes the world's first clinical trial of a neural stem cell therapy for stroke.
View full company profileTherapeutic Areas
Other Undisclosed Drugs
| Drug | Company | Phase |
|---|---|---|
| Preclinical ISAC 1 | Bolt Biotherapeutics | Preclinical |
| Preclinical ISAC 2 | Bolt Biotherapeutics | Preclinical |
| ART12.11 | Artelo Biosciences | Preclinical |
| Novel Vaccines | MSD | Development |
| SLS-009 | Seelos Therapeutics | Discovery |
| Technosphere Platform (New Formulations) | MannKind | Discovery/Preclinical |
| Measovir®-based Prophylactic Vaccine (with Unither) | Oncovita | Research/Pre-clinical |
| Internal sdAb Discovery Program | NanoTag Biotechnologies | Discovery |
| NB-701 | Nerai Biosciences | Discovery |
| Undisclosed Therapeutic Program(s) | Bright Cell | Clinical Trial (Phase unspecified) |
| Biosimilars Pipeline | Intelligent Therapeutics | Pre-clinical/Development |
| Proprietary Therapeutic Pipeline | Excelsior Sciences | Discovery |